The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Dapagliflozin significantly reduced the risk of all-cause mortality or worsening heart failure by 28% in high-risk patients undergoing transcatheter aortic valve implantation (TAVI).

The rate of all-cause mortality was 7.8% in the dapagliflozin arm and 8.9% in the control arm (HR, 0.87 [95% CI, 0.59-1.28]). Regarding safety, genital infections and hypotension were reported ...

Dapagliflozin dose was 10 mg/day, whereas the spironolactone dose varied from 25 mg every other day to 25 mg/day based on eGFR and serum potassium.

Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who ...

Dapagliflozin-treated participants improved their KCCQ scores more than those who received the placebo, regardless of HFimpEF status. Analyzing KCCQ data from one, four, and eight months showed ...

Meeting Coverage > AACE Dapagliflozin Tied to Drop in Hepcidin Levels — Decrease may boost hematocrit and hemoglobin after SGLT-2 inhibitor therapy by Kristen Monaco, Staff Writer, MedPage Today ...

In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease ...

Dapagliflozin (Farxiga) is the first SGLT2 inhibitor approved to treat patients with HFrEF, or a left ventricular ejection fraction less than 40%, according to a press release from the company.